Cancer Vaccines

Shiga Toxin/Peptide Vaccine Elicits Cytotoxic T-Lymphocyte Responses

Published in Vaccine Weekly, February 21st, 2001

by Michelle Marble, staff medical writer -- Researchers in France have developed a cancer vaccine that works without an adjuvant.

"Immunization with peptide or recombinant proteins generally fails to elicit cytotoxic T lymphocytes (CTL), which are thought to play a key role in the control of virus-infected cells and tumor growth," said N. Haicheur and colleagues, University of Paris. "In this study we show that the non-toxic B subunit of Shiga toxin fused to a tumor peptide derived from the mouse mastocytoma P815 can induce specific CTL in mice without the use of adjuvant."

Haicheur et al. published their study in the Journal of Immunology...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-02-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry